DBV Technologies S.A. (FRA:DBV)

Market Cap	988.59M +480.6%
Revenue (ttm)	4.80M +35.8%
Net Income	-125.15M
EPS	-0.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	3.244
Previous Close	3.246
Day's Range	3.244 - 3.244
52-Week Range	1.294 - 4.750
Beta	n/a
RSI	40.88
Earnings Date	Apr 30, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 117
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: DBV

Financial Performance

In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.

Financial numbers in USD